

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Natama, HM; Rovira-Vallbona, E; Sorgho, H; Somé, MA; Traoré-Coulibaly, M; Scott, S; Zango, SH; Sawadogo, O; Zongo, SC; Valéa, I; +5 more... Mens, PF; Schallig, HDFH; Kestens, L; Tinto, H; Rosanas-Urgell, A; (2018) Additional Screening and Treatment of Malaria During Pregnancy Provides Further Protection Against Malaria and Nonmalarial Fevers During the First Year of Life. *The Journal of infectious diseases*. ISSN 0022-1899 DOI: <https://doi.org/10.1093/infdis/jiy140>

Downloaded from: <http://researchonline.lshtm.ac.uk/4647377/>

DOI: <https://doi.org/10.1093/infdis/jiy140>

Usage Guidelines:

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

1 **Type of article: Major article**

2

3 **Additional screening and treatment of malaria during pregnancy provides further protection**
4 **against malaria and non-malaria fevers during the first year of life**

5

6 Hamtandi Magloire Natama^{1,2,3}, Eduard Rovira-Vallbona¹, Hermann Sorgho², M. Athanase
7 Somé², Maminata Traoré-Coulibaly², Susana Scott⁵, Serge Henri Zango^{2,6}, Ousséni Sawadogo²,
8 Sibiri Claude Zongo², Innocent Valéa², Petra F. Mens⁴, Henk D.F.H. Schallig⁴, Luc Kestens^{1,3},
9 Halidou Tinto^{2,6}, Anna Rosanas-Urgell¹

10

11 ¹Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, B 2000, Belgium

12 ²Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro,
13 BP 218, Burkina Faso

14 ³Department of Biomedical Sciences, University of Antwerp, Antwerp, B 2610, Belgium

15 ⁴Department of Medical Microbiology - Parasitology Unit, Academic Medical Centre,
16 Amsterdam, 1105 AZ, The Netherlands

17 ⁵Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
18 Medicine, London, WC1E7HT, UK

19 ⁶Centre Muraz, Bobo Dioulasso, BP 390, Burkina Faso

20

21 **Running title:** Decreased malaria risk in infants

22 **Brief summary of the article main's point**

23 This study examined the potential benefits of malaria in pregnancy (MiP) preventive strategies
24 in infants and showed, that enhanced screening and treatment, in addition to standard IPTp-SP,
25 may provide additional protection against malaria and non-malaria fevers in early infancy.

26 **Corresponding author:** Anna Rosanas-Urgell; Department of Biomedical Sciences, Institute of
27 Tropical Medicine, Antwerp, B 2000, Belgium; Email: arosanas@itg.be; Telephone: +32 474 952
28 797.

29 **Abstract**

30 **Background:** Although consensus on that malaria in pregnancy (MiP) increases the risk of malaria
31 in infancy, and eventually non-malaria fevers (NMFs), there is a lack of conclusive evidences of
32 benefits of MiP preventive strategies in infants.

33 **Methods:** In Burkina Faso, a birth cohort study was nested to a clinical trial assessing the
34 effectiveness of a community-based scheduled screening and treatment of malaria in combination
35 with intermittent preventive treatment with sulfadoxine-pyrimethamine (CSST/IPTp-SP) to
36 prevent placental malaria. Clinical episodes and asymptomatic infections were monitored over one-
37 year follow-up to compare the effect of CSST/IPTp-SP and standard IPTp-SP on malaria and
38 NMFs.

39 **Results:** Infants born during low-transmission season from mothers receiving CSST/IPTp-SP had
40 a 26% decreased risk of experiencing a first clinical episode (HR, 0.74 [95% CI, 0.55- 0.99]; $P =$
41 .047). CSST/IPTp-SP interacted with birth season and gravidity to reduce the incidence of NMFs.
42 No significant effects of CSST/IPTp-SP on the incidence of clinical episodes, parasite density and
43 *Plasmodium falciparum* infections were observed.

44 **Conclusions:** Our findings indicate that CSST/IPTp-SP strategy may provide additional protection
45 against both malaria and NMFs in infants during the first year of life, and suggest that malaria
46 control interventions during pregnancy could have long-term benefits in infants.

47
48 **Key words:** Malaria, *Plasmodium falciparum*, pregnancy, prevention, infancy, non-malaria fevers

49

50 **Introduction**

51 Malaria in pregnancy (MiP) causes significant adverse health effects in both mothers and their
52 newborn children and, is estimated to account for between 75000 and 200000 infant deaths a
53 year[1]. While maternal mortality is often associated with severe maternal anaemia, infant deaths
54 are due to complications during pregnancy, such as foetal growth restriction, foetal anaemia, pre-
55 term deliveries and congenital malaria [1].

56
57 The hallmark of MiP due to *Plasmodium falciparum* is placental malaria (PM), characterized by
58 sequestration of infected erythrocytes in intervillous spaces of the placenta through binding to
59 chondroitin sulfate A on syncytiotrophoblast [2]. Increasing evidence from birth cohort studies
60 have shown that PM is associated with increased susceptibility to malaria during infancy [3–8],
61 probably due to the acquisition of immune tolerance to parasite antigens during in utero exposure.
62 Likewise, the development of a tolerogenic environment as a result of PM might also be the cause
63 for increased infant-susceptibility to non-malaria fevers (NMFs) [9].

64
65 Intermittent preventive treatment with at least three full sulfadoxine-pyrimethamine (IPTp-SP)
66 doses (administered at least one month apart), combined with the use of insecticide treated bed-
67 nets (ITNs), is currently the recommended strategy for preventing MiP in most malaria endemic
68 countries, as it reduces the risk of PM at delivery, neonatal mortality and infants' low birth weight
69 (LBW) [10]. However, the effectiveness of this IPTp-SP based intervention is threatened by the
70 growing spread of parasites with increasing resistance to SP [11]. In this context, studies assessing

71 the impact of novel anti-malarial interventions during pregnancy, not only on pregnant women but
72 also on their infants, are urgently needed as information to date is scarce and inconclusive [12,13].

73
74 A multicentre cluster-randomized controlled trial (COSMIC) was recently conducted in three west-
75 African countries with high (Burkina Faso and Benin) and low (The Gambia) malaria transmission,
76 to assess the protective efficacy of adding community-scheduled screening and treatment of
77 malaria during pregnancy (CSST) to standard IPTp-SP (CSST/IPTp-SP). The CSST extension
78 strategy was implemented monthly by community health workers using rapid diagnostic test
79 (RDT). The aim of the combined CSST/IPTp-SP strategy was to provide additional opportunities
80 to detect and treat malaria infections during pregnancy and reduce the prevalence of PM [14].

81 In this study, we have followed infants born to mothers at the Burkina Faso site in the COSMIC
82 trial, with the aim to evaluate whether CSST/IPTp-SP compared to IPTp-SP alone was effective in
83 protecting infants from malaria and NMFs during the first year of life.

84

85 **Material and methods**

86 **Study site**

87 The study was conducted in Nanoro, a rural area with high malaria transmission located in the
88 central-west region of Burkina Faso. Malaria transmission occurs year-round and is highly
89 seasonal. Transmission peaks between July and December overlapping with the rainy season (July
90 to November). *P. falciparum* is the main species responsible for transmission, with a prevalence of
91 90%. The prevalence of peripheral and placental *P. falciparum* infections at delivery during the
92 high-transmission season is estimated at 32% and 34% respectively [15]. In 2015, approximately
93 7.4 million of clinical malaria cases and 32000 malaria related deaths were recorded in Burkina
94 Faso [16]. Out of 91154 clinical malaria episodes that occurred in Nanoro health district in 2016,

95 approximately 55% were detected among infants below five years of age [17].

96

97 **Study design and participants**

98 This was an observational birth cohort study of infants born to women who participated in the
99 COSMIC trial (NCT01941264), described in detail elsewhere [14]. In COSMIC trial it was
100 assumed that CSST/IPTp-SP strategy would decrease PM by 30%. Following this assumption, and
101 considering the prevalence of malaria infection in a 12-month birth cohort study in Benin (35%)
102 [4], as at the time of recruitment there were no such data available in Burkina Faso, we assumed
103 that the impact of the intervention will decrease *P. falciparum* infection during the first year of life
104 by 30%, from 35% to 25%. With a 1:1 ratio to provide a power of at least 80% with 5% precision,
105 the required sample size was estimated to 350 newborns in each study arm. To account for loss to
106 follow-up and exclusion criteria at delivery, a total of 752 pregnant women from COSMIC trial
107 (376 in each arm) were enrolled between March 2014 and June 2015 onto the current study. Written
108 informed consent was obtained from all mothers and ethical approval was obtained from the
109 institutional ethics committees of Centre Muraz, Bobo Dioulasso, Burkina Faso (006-2014/CE-
110 CM), the Institute of Tropical Medicine, Antwerp, Belgium (953/14) and University Hospital in
111 Antwerp (UZA), Belgium (14/26/277).

112

113 **Recruitment and follow-up procedures**

114 Pregnant women participating in the COSMIC trial were invited to participate in the present study
115 at any antenatal care visits but the enrollment of mother-child pairs onto this study occurred at time
116 of delivery. Exclusion criteria at time of delivery were maternal death, stillbirth and presence of
117 major congenital malformation, chronic diseases or signs of cerebral asphyxia. Maternal peripheral
118 blood was collected by finger-prick to prepare blood smears and blood spots on filter paper for

119 subsequent malaria diagnosis. A tissue section was collected from the maternal side of the placenta
120 and preserved into 10% neutral buffered formalin at 4°C for histological examination within the
121 COSMIC trial. A drop of placental blood was also spotted on filter paper. Infants were followed
122 for 12 months and malaria infections were detected actively and passively. Active case detection
123 consisted of four cross-sectional surveys conducted at 3, 6, 9 and 12 months of age. For each
124 survey, blood films and blood spots on filter papers were collected for examination by light
125 microscopy (LM) and quantitative real-time polymerase chain reaction (qPCR), respectively. For
126 passive clinical case detection, mothers were encouraged to bring their offspring to the health
127 centre if they displayed any signs of illness. Infants presenting with fever (axillary temperature
128 $\geq 37.5^{\circ}\text{C}$) on examination or a history of fever in the previous 24 hours, were screened for malaria
129 infection using RDT (SD-Bioline Malaria Ag P.f®, Standard Diagnostic, Inc, Korea) and, if
130 positive, treated according to national guidelines. Malaria diagnosis was subsequently confirmed
131 by LM and qPCR.

132

133 **Laboratory methods**

134 LM readings were taken according to standard procedures by two independent experienced readers
135 [18]. A third reader was consulted in cases of discrepancies. Dried blood spots on filter papers were
136 used for DNA extraction (QIAamp 96 DNA blood kit, Qiagen, Germany) and, *P. falciparum*
137 detection and quantification by *Pf*-varATS qPCR using procedures described elsewhere [15]. The
138 limit of detection of the *Pf*-varATS qPCR was estimated at 0.1 parasite/ μL and qPCR was used as
139 reference malaria diagnostic test. Data on past history of malaria infections during pregnancy and
140 histological examinations of placental tissue data were obtained from the COSMIC trial [14].

141

142 **Data analysis and definition of terms**

143 Data were double entered into the study databases (OpenClinica, community version or Excel,
144 Microsoft, USA) and analyzed with STATA 12.0 (StataCorp, USA). The baseline characteristics
145 of mother-child pairs were compared between the study arms. Continuous data normally distributed
146 and categorical variables were analyzed using the t-test and the χ^2 test, respectively. Non-normally
147 distributed data were described using median and interquartile ranges (IQR).

148 The risk of malaria and NMFs during the first year of life was analyzed using the following
149 outcomes: time from birth to the first clinical malaria episode, incidence of clinical malaria
150 episodes, parasite density, prevalence of *P. falciparum* infection and incidence of NMFs. The main
151 exposure was the MiP intervention (CSST/IPTp-SP or IPTp-SP). The effect of prenatal malaria
152 exposure -defined as maternal peripheral and placental infections- on outcome was investigated in
153 a separate analysis. Maternal age, gravidity, ITN usage by mothers, birth season and newborn sex
154 were considered as potential confounders. Twin infants were excluded from the analysis.

155 The effect of the interventions on time-to-first clinical malaria episode was analyzed using Cox
156 proportional univariate and multivariate analyses, while Kaplan-Meier analysis was used to
157 calculate the survival curves. Because MiP preventive strategies may have a causal effect on
158 pregnancy outcomes and subsequently an effect on the risk of malaria in infancy, neither low birth
159 weight (LBW) nor maternal peripheral and PM infections at delivery were used as covariates in
160 the multivariate Cox proportional models. The effect of the interventions on the incidence of
161 clinical malaria episodes and NMFs was investigated using Poisson regression or negative binomial
162 models depending on the goodness-of-fit tests with results expressed as incidence rate ratios (IRRs
163 with 95% confidence interval (CI)). Linear regression analysis was used for log-transformed
164 parasite densities and logistic regression models for *P. falciparum* infection excluding censored
165 infants. Variables with a *P* value < .1 in univariate analyses were included in multivariable

166 analyses. A *P* value < .05 was considered to be statistically significant. The definitions of terms
167 and the different categories of prenatal malaria exposure used in the present study are shown in
168 Supplementary Table 1.

169

170 **Results**

171

172 **Study population**

173 The flow chart of the birth cohort study is shown in Figure 1. Out of the 761 infants (from 752
174 mothers) enrolled in the study, 669 (88%) completed the 12-months follow-up. Of the remaining
175 92 infants, 41 were lost to follow-up, 38 had consent withdrawn mainly because of migration from
176 the study area and 13 died (seven neonatal deaths and six within 1 to 12 months). In total, 734 of
177 the initial 761 infants were included in the survival analysis (367 in each COSMIC study arm). The
178 infants excluded from the analysis were the seven neonates who died before four weeks of age and
179 the 20 live twins although they completed follow-up. The cross-sectional surveys conducted at 3,
180 6, 9 and 12 months of age included 678 (92.4%), 631 (86%), 587 (80%) and 638 (86.9%) infants
181 respectively. Table 1 presents the characteristics of the mothers and infants as a whole and by MiP
182 intervention group. The baseline maternal and infant demographic and parasitological
183 characteristics were similar between the participants in the CSST/IPTp-SP and standard IPTp-SP
184 arms.

185

186 **Malaria infections**

187 Overall incidence of clinical malaria in the study population was 1.03 episodes per child-year (a
188 total of 717 cases over 8335.18 months at risk) and the median survival time from birth to the first
189 clinical malaria episode was 9.9 months. Nearly 59% (433/734) of the infants experienced at least

190 one clinical malaria episode during the first 12 months of life. The prevalence of asymptomatic
191 infections as detected by qPCR in the cross-sectional surveys was 17.70% (120/678) at 3 months,
192 20.13 (127/631) at 6 months, 18.40 (108/587) at 9 months and 30.41% (194/638) at 12 months.
193 Median qPCR-parasite density during clinical malaria episodes (10826.50 [IQR 876.50-38021.50]
194 parasites/ μ L) was significantly higher than that during asymptomatic infections (379 [IQR 1.94-
195 3932.5] parasites/ μ L, $P < .0001$).

196

197 **Effect of CSST/IPTp-SP strategy on time-to-first clinical malaria episode**

198 Although time-to-first clinical malaria episode was not significantly different between the two
199 study arms in univariate and multivariate analyses (Table 2), birth season was found to interact and
200 significantly modify the effect of CSST/IPTp-SP on time-to-first clinical malaria episodes. We
201 observed that infants born to mothers in the CSST/IPTp-SP arm during malaria low-transmission
202 season had a 26% decreased risk of a first clinical malaria episode compared with those born to
203 mothers in the IPTp-SP arm (HR, 0.74 [95% CI, 0.55-0.99]; $P = .047$). By contrast, no significant
204 differences were observed between the two arms for infants born during malaria high-transmission
205 season (HR, 0.97 [95% CI, 0.76-1.25]; $P = .846$). That difference of the effect of CSST/IPTp-SP
206 on time-to-first clinical malaria episode according to birth season was further illustrated in Kaplan-
207 Meier survival curves (Figure 2).

208 We investigated whether the observed effect of CSST/IPTp-SP could be explained by differences
209 in prenatal malaria exposure. Table 3 shows that the increased risk of time-to-first clinical malaria
210 episode was associated with peripheral infection during pregnancy and past PM ($P = .009$ and P
211 $= .020$, respectively) but not with active PM ($P = .177$), after adjusting by gravidity, birth season
212 and LBW. Thus, the effect of CSST/IPTp-SP on time-to-first clinical malaria episode was more

213 likely to be attributable to the impact on malaria infection during pregnancy rather than to active
214 PM.

215 The two COSMIC study arms had a similar effect on infant parasite density during the first clinical
216 malaria episode (6557.50 [IQR, 609.00-28484.50] parasites/ μ L in CSST/IPTp-SP vs. 4549.00
217 [IQR, 380.50-19627.75] parasites/ μ L in standard IPTp-SP). Similar lack of association was
218 observed on parasitaemia in all clinical episodes even after adjusting for gravidity and sex
219 (coefficient, 1.10 [95% CI, 0.82-1.47]; $P = .526$) (Supplementary Table 2).

220

221 **Effect of CSST/IPTp-SP strategy on the incidence of clinical malaria episodes**

222 Table 4 shows results of the analysis of the effect of the CSST/IPTp-SP strategy on the incidence
223 of clinical malaria episodes including repeated malaria attacks per infant during the first year of
224 life. We found no significant differences between CSST/IPTp-SP and IPTp-SP after adjusting for
225 birth season (adjusted IRR, 0.95 [95% CI, 0.82-1.10]; $P = .459$). Moreover, no significant
226 differences were observed in the stratified analysis by birth season (high-transmission season: IRR,
227 0.99 [95% CI, 0.82-1.20]; $P = .941$; low-transmission season IRR, 0.91 [95% CI, 0.72-1.14]; $P =$
228 .409).

229

230 **Effect of CSST/IPTp-SP strategy on *P. falciparum* infections**

231 In total, 553 of 690 infants (80.14%) experienced at least one symptomatic or asymptomatic
232 infection during the first year of life. The odds of experiencing a *P. falciparum* infection in infants
233 born to mothers in the CSST/IPTp-SP group was not significantly different from that of children
234 born to mothers in the IPTp-SP group, even after controlling for gravidity (adjusted OR, 1.20 [95%
235 CI, 0.82-1.74]; $P = .348$) (Supplementary Table 3). There were also no statistical differences

236 between the groups in terms of the proportions of asymptomatic infections in infants, regardless of
237 the time of screening (Supplementary Table 4).

238

239 **Effect of CSST/IPTp-SP strategy on the incidence of NMFs**

240 A total of 805 NMFs episodes (incidence, 1.16 per child-year) were recorded in the 734 infants
241 analyzed during their first year of life. Table 5 presents the stratified analysis by birth season and
242 gravidity that were found to interact with CSST/IPTp-SP strategy to modify infant's susceptibility
243 to NMFs. Infants born to CSST/IPTp-SP mothers during malaria high-transmission season had a
244 significantly lower risk of developing NMFs than their counterpart born to mothers receiving the
245 standard IPTp-SP (adjusted IRR, .79 [95% CI, 0.64-0.98]; $P = .031$) (Table 5). When stratifying
246 the analysis by gravidity, only the offspring of multigravid women in the CSST/IPTp-SP group
247 were significantly protected against NMFs (adjusted IRR, .78 [95% CI, 0.63-0.97]; $P = .027$). We
248 did not observe any significant associations between prenatal malaria exposure and occurrence of
249 NMFs (Supplementary Table 5).

250

251 **Discussion**

252 In this prospective birth cohort study we found that, compared with standard IPTp-SP strategy,
253 CSST/IPTp-SP significantly increased time-to-first clinical malaria episode in infants born during
254 malaria low-transmission season, and protected against the occurrence of NMFs in those born
255 during malaria high-transmission season. Due to the transmission seasonality of malaria and NMFs
256 in Burkina Faso, CSST/IPTp-SP strategy appears to have different impact in women who had the
257 main course of their pregnancy during malaria high-transmission season (and most probably gave
258 birth during malaria low-transmission season) compared to those who were pregnant during

259 malaria low-transmission season (and most probably gave birth during malaria high-transmission
260 season).

261
262 Our findings showed, for the first time, that MiP preventive treatments may provide protection
263 against malaria in infants during the first year of life, in addition to the known protection against
264 adverse pregnancy outcomes. New MiP strategies should thus be evaluated not only for the
265 protective effect on pregnancy outcomes but also the potential additional long-term benefits in
266 infants. To our knowledge, only one study has compared the incidence of malaria in infants born
267 to mothers who received either IPTp-SP or screening and treatment with RDT and artemether-
268 lumefantrine (ISTp-AL) during antenatal care visits, without IPTp-SP [13]. The authors found no
269 differences in the risk of clinical malaria episodes during early life and observed that the two
270 interventions had similar performance in preventing PM [13]. In comparison, the strategy of
271 combining a CSST with the standard IPTp-SP increases the chances of clearing parasite infections
272 when the protective efficacy of IPTp-SP is waned, thus reducing the risk of long-term parasite
273 carriage during pregnancy. Indeed, thanks to the enhanced screening, the proportion of malaria
274 infections detected by RDT amongst women in the CSST/IPTp-SP arm was significantly higher
275 than that among women in the routine IPTp-SP arm (Table 1).

276
277 Remarkably, the impact of the CSST/IPTp-SP strategy on the risk of malaria in infancy was evident
278 in infants born to women who had the main course of their pregnancy during malaria high-
279 transmission season (and thus born during low-transmission season), while the two interventions
280 performed similarly when the main course of pregnancy was during the low-transmission season.
281 Therefore, we hypothesized that this effect of CSST/IPTp-SP is attributable to the additional
282 reduction in parasite exposure that was not prevented by the standard IPTp-SP owing to the fact

283 that maternal peripheral infections were associated with an increased risk of malaria in infants
284 (Table 3). The observation that past PM and peripheral infections during pregnancy, but not active
285 PM, were associated with a risk of clinical malaria suggests that preventing infections at early stage
286 of pregnancy may have a critical effect on future infant susceptibility. Most studies to date have
287 focused in looking at the association between PM and malaria risk, probably thus missing the
288 overall effect of preventing all infections [3–8]. Our findings are supported by a recent study that
289 showed that the timing of prenatal malaria exposure had a pivotal role on the polarization of the
290 foetal immune responses [19]. In this context, the study that we are currently conducting on the
291 relationships between types of prenatal malaria exposure, innate immune responses at birth and the
292 subsequent risk of malaria in early infancy will provide further understanding on how maternal
293 infections modulate newborn’s immune responses and affect risk of malaria during the first year
294 of life.

295 CSST/IPTp-SP strategy significantly increased time from birth to the first clinical malaria episode
296 compared with the standard IPTp-SP in infants born during the low transmission season,
297 however this effect did not translate into a significant reduction of malaria incidence in the
298 same group. Although the difference was non-significant, the overall clinical malaria incidence
299 was also reduced in these infants suggesting that a MiP intervention with a stronger effect size
300 on time to first infection would further reduce malaria incidence in infancy. In this study, the
301 observed effect of the CSST/IPTp-SP intervention may have been limited by the sensitivity of the
302 RDT used during screenings (limit of detection of approximately 200 parasites/ μ L) [20]. It is thus
303 reasonable to assume that the lack of effect observed in infants born to mothers who were mostly
304 pregnant during the low-transmission season might be due to the reduction of transmission intensity
305 during this time and to the possibility that RDTs might have missed a considerable proportion of

306 low-density infections [21]. We are tempted to speculate that the effect of the CSST/IPTp-SP
307 intervention could be increased with the use of high-sensitivity diagnostic tools capable of
308 detecting low-density infections. In this regard, high-sensitivity RDTs currently used in field
309 testing (PATH) [22] and molecular strategies such as LAMP [23], ~~which have a limit of detection~~
310 ~~of 10-20 parasites/ μ l and < 1 parasite/ μ L respectively,~~ are promising tools to improve screening
311 strategies.

312
313 It is noteworthy that the CSST/IPTp-SP intervention was also associated with a reduced incidence
314 of NMFs during the first year of life in infants born during malaria high-transmission season but
315 not in those born during malaria low-transmission season. Therefore, it is unlikely that the same
316 mechanism underlies the susceptibility to NMF since this protection, ~~which is in agreement with a~~
317 ~~previous study [24],~~ was independent of PM, even after exploring the association with different
318 categories of prenatal malaria exposure. Nevertheless, several studies have reported modulation of
319 the foetal immune system by malaria infections during pregnancy [19,25,26]. In addition to
320 malaria-specific immune responses, these modifications may also affect specific immunity to other
321 pathogens responsible of NMFs [27,28], such as those caused by blood stream infections,
322 gastrointestinal infections, acute respiratory infections, urinary tract infections and arbovirus
323 infections [29,30].

324 Moreover, the CSST/IPT-SP intervention was found to interact with gravidity to significantly
325 protect infants born to multigravid women but not these born to either secundigravid (non-
326 significant protection) or primigravid women (non-significant increased risk). These findings
327 suggest that, through the modification of prenatal malaria exposure (which may differ
328 depending on gravidity), the CSST/IPTp-SP intervention alters or prime the development of

329 fetal immune system affecting immunity to pathogens that are responsible of NMFs in early
330 infancy. To gain further an understanding of how MiP preventive interventions can modulate the
331 immune system to impact infant susceptibility to NMFs, new studies should include diagnosis of
332 NMFs.

333

334 **Conclusion**

335 In this study we have shown that, compared with standard IPTp-SP, CSST/IPTp-SP significantly
336 decreases the risk of experiencing a first clinical malaria episode and also interact with birth season
337 and gravidity to reduce the incidence of NMFs during the first year of life. Altogether, our findings
338 suggest that MiP preventive strategies that effectively reduce exposure to malaria parasites during
339 pregnancy could provide additional protection against both malaria and NMFs in early infancy and
340 therefore, have long-term benefits in infants.

341

342 **Notes:**

343

344 **Acknowledgments.** We are indebted to the mothers and their offspring who participated in this
345 study. We thank nurses, field workers, field supervisors, data managers and laboratory workers at
346 the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso, who played an important role for
347 the successful completion of the study. We also acknowledge the research team at the Malariology
348 Unit, Institute of Tropical Medicine (ITM), Belgium.

349

350 **Financial support.** This study was supported by the Belgium Directorate General for Development
351 Cooperation (DGB, Belgium) and COSMIC project funded by European Union Seventh
352 Framework Programme (FP7/2002-2016) under grant agreement n° 305662– COSMIC).

353
354 **Potential conflicts of interest.** The authors declare no competing interests.
355
356 **Presentation at meetings.** Data of this study have been partly presented at the European Congress
357 of Tropical Medicine and International Health (ECTMIH) held from 16-20 October 2017 in
358 Antwerp, Belgium (Abstract number 8S1.1).

359
360 **Correspondence and requests for reprints.** Any correspondence should be addressed to Anna
361 Rosanas-Urgell, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, B
362 2000, Belgium; email: arosanas@itg.be; telephone: +32 474 952 797.

363

364 **References**

- 365 1. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in
366 malaria-endemic areas. *Am J Trop Med Hyg* **2001**; 64:28–35.
- 367 2. Crocker IP, Tanner OM, Myers JE, Bulmer JN, Walraven G, Baker PN.
368 Syncytiotrophoblast degradation and the pathophysiology of the malaria-infected placenta.
369 *Placenta* **2004**; 25:273–282.
- 370 3. Hesran JY Le, Cot M, Personne P, et al. Maternal placental infection with *Plasmodium*
371 *falciparum* and malaria morbidity during the first 2 years of life. *Am J Epidemiol* **1997**;
372 146:826–31.
- 373 4. Port A Le, Watier L, Cottrell G, et al. Infections in infants during the first 12 months of
374 life: role of placental malaria and environmental factors. *PLoS One* **2011**; 6:e27516.
- 375 5. Schwarz NG, Adegnika AA, Breitling LP, et al. Placental Malaria Increases Malaria Risk
376 in the First 30 Months of Life. *Clin Infect Dis* **2008**; 47:1017–1025.

- 377 6. Mutabingwa TK, Bolla MC, Li JL, et al. Maternal malaria and gravidity interact to modify
378 infant susceptibility to malaria. *PLoS Med* **2005**; 2:1260–1268.
- 379 7. Malhotra I, Dent A, Mungai P, et al. Can prenatal malaria exposure produce an immune
380 tolerant phenotype? A prospective birth cohort study in Kenya. *PLoS Med* **2009**;
381 6:e1000116.
- 382 8. Sylvester B, Gasarasi DB, Aboud S, Tarimo D, Massawe S, Mpembeni R. Prenatal
383 exposure to *Plasmodium falciparum* increases frequency and shortens time from birth to
384 first clinical malaria episodes during the first two years of life : prospective birth cohort
385 study. *Malar J* **2016**; 15:379.
- 386 9. Rachas A, Port A Le, Cottrell G, et al. Placental Malaria is Associated With Increased Risk
387 of Nonmalaria Infection During the First 18 Months of Life in a Beninese Population. *Clin*
388 *Infect Dis* **2012**; 55:672–678.
- 389 10. Kayentao K, Garner P, Eijk a M Van, et al. Intermittent preventive therapy for malaria
390 during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of
391 low birth weight in Africa: Systematic review and meta-analysis. *JAMA - J Am Med*
392 *Assoc* **2013**; 309:594–604.
- 393 11. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent
394 treatment to prevent pregnancy malaria does not confer benefit in an area of widespread
395 drug resistance. *Clin Infect Dis* **2011**; 53:224–230.
- 396 12. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in
397 infants: an old problem with present consequences. *Malar J* **2014**; 13:271.
- 398 13. Awine T, Belko MM, Oduro AR, et al. The risk of malaria in Ghanaian infants born to
399 women managed in pregnancy with intermittent screening and treatment for malaria or
400 intermittent preventive treatment with sulfadoxine / pyrimethamine. *Malar J* **2016**; 15:46.

- 401 14. Scott S, Mens PF, Tinto H, et al. Community-based scheduled screening and treatment of
402 malaria in pregnancy for improved maternal and infant health in The Gambia, Burkina
403 Faso and Benin: study protocol for a randomized controlled trial. *Trials* **2014**; 15:340.
- 404 15. Natama HM, Ouedraogo DF, Sorgho H, et al. Diagnosing congenital malaria in a high-
405 transmission setting : clinical relevance and usefulness of *P. falciparum* HRP2-based
406 testing. *Sci Rep* **2017**; 7:1–10.
- 407 16. World Health Organization. World Malaria Report 2016. Available at:
408 <http://www.who.int/malaria/publications/world-malaria-report-2016/en/>. Accessed 17 May
409 2017.
- 410 17. Burkina Faso: Ministère de la santé. Annuaire statistique 2016. Available at:
411 <http://www.sante.gov.bf>. Accessed 10 May 2017.
- 412 18. World Health Organization. Basic Malaria Microscopy: Part I. Learner’s Guide (Second
413 edition) 1-83. Available at:
414 http://www.who.int/publications/2010/9789241547826_eng.pdf. Accessed 20 April 2017.
- 415 19. Prah M, Jagannathan P, McIntyre TI, et al. Timing of in utero malaria exposure influences
416 fetal CD4 T cell regulatory versus effector differentiation. *Malar J* **2016**; 15:497.
- 417 20. World Health Organization. Malaria Rapid Diagnostic Test Performance: results of WHO
418 product testing of malaria RDTs: Round 7 (2015-2016). Available at:
419 [http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/product-testing-](http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/product-testing-round7/en/)
420 [round7/en/](http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/product-testing-round7/en/). Accessed 4 October 2017.
- 421 21. Ruizendaal E, Schallig HD, Scott S, et al. Evaluation of malaria screening during
422 pregnancy with rapid diagnostic tests performed by community health workers in Burkina
423 Faso, West Africa. *Am J Trop Med Hyg* **2017**; 97:1190–1197.
- 424 22. Das S, Jang IK, Barney B, et al. Performance of a High-Sensitivity Rapid Diagnostic Test

- 425 for *Plasmodium falciparum* Malaria in Asymptomatic Individuals from Uganda and
426 Myanmar and Naive Human Challenge Infections. *Am J Trop Med Hyg* **2017**; 97:1540–
427 1550.
- 428 23. Serra-Casas E, Manrique P, Ding XC, et al. Loop-mediated isothermal DNA amplification
429 for asymptomatic malaria detection in challenging field settings: Technical performance
430 and pilot implementation in the Peruvian Amazon. *PLoS One* **2017**; 12: e0185742.
- 431 24. Asante KP, Owusu-agyei S, Cairns M, et al. Non-malaria fevers in a high malaria endemic
432 area of Ghana. *BMC Infect Dis* **2016**; 16:327.
- 433 25. Flanagan KL, Halliday A, Burl S, et al. The effect of placental malaria infection on cord
434 blood and maternal immunoregulatory responses at birth. *Eur J Immunol* **2010**; 40:1062–
435 1072.
- 436 26. Breitling LP, Fendel R, Mordmueller B, Adegnika A a, Kremsner PG, Luty AJF. Cord
437 blood dendritic cell subsets in African newborns exposed to *Plasmodium falciparum* in
438 utero. *Infect Immun* **2006**; 74:5725–9.
- 439 27. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells
440 is lost during *P. falciparum* malaria. *Nature* **1984**; 312:449–450.
- 441 28. French N, Nakiyingi J, Lugada E, Watera C, Whitworth J a, Gilks CF. Increasing rates of
442 malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. *AIDS*
443 **2001**; 15:899–906.
- 444 29. World Health Organization. WHO informal consultation on fever management in
445 peripheral health care settings: a global review of evidence and practice. Available at:
446 http://www.who.int/malaria/mpac/who_consultation_fever_management_presentation.pdf.
447 Accessed 30 June 2017.
- 448 30. Maltha J, Guiraud I, Kaboré B, et al. Frequency of severe malaria and invasive bacterial

449 infections among children admitted to a rural hospital in Burkina Faso. PLoS One **2014**; 9:
 450 e89103.

451

452

453

454

455

456

457

458 **Tables**

459

460 **Table 1: Baseline characteristics of study participants**

461

Category, characteristics	Total study participants (N=734)	Standard IPTp-SP (N=367)	CSST/IPTp-SP (N=367)	P value
Maternal characteristics				
Age—years, Mean±SD	26.4±6.2	26.0±6.2	26.7±6.2	.139
Gravidity—no. (%)				.674
Primigravid	132 (18.0)	68 (18.5)	64 (17.4)	
Secundigravid	117 (15.9)	62 (16.9)	55 (15.0)	
Multigravid	485 (66.1)	237 (64.6)	248 (67.6)	
SP doses uptake, Mean±SD	2.68±0.97	2.64 ±0.98	2.72±0.97	.236
Total maternal peripheral infections detected by RDT* —no.(%)	159 (21.7)	50 (13.6)	109 (29.7)	< .001
Maternal peripheral infection at deliver by qPCR (MPI)**—no. (%)	152 (21.3)	84 (23.7)	68 (18.9)	.119
Placental malaria (PM)**—no.(%)				

By qPCR	160 (22.8)	86 (24.4)	74 (21.3)	.328
By histology (acute, chronic, past infections)	447 (67.3)	215 (67.7)	232 (67.1)	.878
Gestational age at delivery—no. (%)				.199
Pre-term delivery (28-36 weeks)	31 (4.2)	12 (3.3)	19 (5.2)	
Term delivery (>36 weeks)	703 (95.8)	355 (96.7)	348 (94.8)	
Insecticide treated net (ITN) use—no. (%)	574 (78.2)	278 (75.7)	296 (80.7)	.108
Infant characteristics				
Sex—no. (%)				.301
Male	356 (48.5)	171 (46.6)	185 (50.4)	
Female	378 (51.5)	196 (53.4)	182 (49.6)	
Birth season—no. (%)				.254
High-transmission (July-December)	455 (62.0)	235 (64.0)	220 (59.9)	
Low-transmission (January-June)	279 (38.0)	132 (36.0)	147(40.1)	
Birth weight—g, Mean±SD	3012.7±422.2	2984.8±411.1	3040.6±431.7	.073
Low birth weight (<2500) —no. (%)	60 (8.2)	35 (9.5)	25 (6.8)	.178

NOTE. IPTp-SP, Intermittent Preventive Treatment during pregnancy with Sulfadoxine-Pyrimethamine; CSST/IPTp-SP, community-based scheduled screening and treatment of malaria during pregnancy with artemether-lumefantrine plus standard IPTp-SP for malaria in pregnancy prevention and control; SD, Standard Deviation; g, gram. *Positive RDT cases diagnosed (at home visits (CSST/IPTp-SP arm)) and unscheduled visits (both IPTp-SP and CSST/IPTp-SP arms)) and confirmed by light microscopy. ** Missing: MPI detected by qPCR (N=713): Standard IPTp-SP =353, CSST/IPTp-SP=359; PM detected by qPCR (N=701): Standard IPTp-SP =353, CSST/IPTp-SP= 348; PM detected by histology (N=664): Standard IPTp-SP=318, CSST/IPTp-SP= 346; CM (N=703): Standard IPTp-SP=352, CSST/IPTp-SP=351.

462

463

464

465

466
 467
 468
 469
 470
 471
 472
 473
 474

Table 2: Effect of CSST/IPTp-SP on time-to-first clinical malaria episode by Cox proportional hazards analysis

Characteristic	Risk factor	Unadjusted		Adjusted*	
		HR (95% CI)	P value	HR (95% CI)	P value
Overall cohort analysis					
MiP Intervention strategy	Standard IPTp-SP	1		1	
	CSST/IPTp-SP	0.90 (0.75-1.09)	.293	0.88 (0.73-1.07)	.205
Gravidity	Multigravid	1		1	
	Secundigravid	1.25 (0.97-1.61)	.081	1.22 (0.94-1.56)	.129
	Primigravid	0.98 (0.75-1.28)	.863	0.97 (0.75-1.27)	.851
Mother's age	>30	1			
	21-30	1.07 (0.85-1.35)	.572		
	≤20	1.03 (0.77-1.36)	.856		
ITN use	No	1			
	Yes	1.10 (0.85-1.44)	.462		
Birth season	Low-transmission	1		1	
	High-transmission	0.69 (0.57-0.84)	.001	0.69 (0.56-0.83)	.001
Newborn sex	Male	1			
	Female	0.90 (0.75-1.09)	.284		

Stratified analysis (CSST/IPTp-SP vs standard IPTp-SP (ref))

Birth season	Low-transmission	0.74 (0.55-0.99)	.047
	High-transmission	0.97 (0.76-1.25)	.846

NOTE. MiP, malaria in pregnancy; ITN, insecticide treated net; HR, hazard ratio; CI, confidence interval

*Adjusted by variables that showed a *P* value < .1 in univariate analysis

475

476

477 **Table 3. Cox proportional analysis assessing the effect of prenatal malaria exposure on time**

478 **to first clinical malaria episode**

479

Characteristic	Risk factor	Unadjusted		Adjusted*	
		HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value
Prenatal malaria exposure	Non-infected mothers	1		1	
	Infected mothers	1.56 (1.09-2.23)	.016	1.62 (1.12-2.32)	.009
	Past PM mothers	1.39 (1.04-1.86)	.026	1.42 (1.06-1.91)	.020
	Active PM mothers	1.12 (0.78-1.61)	.550	1.30 (0.89-1.91)	.177
LBW	No	1		1	
	Yes	1.55 (1.13-2.13)	.007	1.55 (1.10-2.18)	.011
Gravidity	Multigravid	1		1	
	Secundigravid	1.25 (0.97-1.61)	.081	1.13 (0.86-1.47)	.384
	Primigravid	0.98 (0.75-1.27)	.863	0.97 (0.73-1.30)	.865
Mother's age	>30	1			
	21-30	1.07 (0.85-1.35)	.572		
	≤20	1.03 (0.77-1.36)	.856		
Birth season	Low-transmission	1			
	High-transmission	0.69 (0.57-0.84)	.001	0.69 (0.56-0.86)	.001
Newborn sex	Male	1			

	Female	0.90 (0.75-1.09)	.284
ITN use	No	1	
	Yes	1.10 (0.85-1.44)	.462

NOTE. PM, placental malaria; ITN, insecticide treated net; LBW, low birth weight; CI, confidence interval; HR, hazard ratio. *Adjusted by variables that showed a *P* value < .1 in univariate analyses.

480
481
482
483 **Table 4: Effect of CSST/IPTp-SP on clinical malaria incidence during the first 12 months**
484 **of life by Poisson regression analysis**

485

Characteristic	Risk factor	Univariate		Multivariate*	
		IRR (95% CI)	<i>P</i> value	IRR (95% CI)	<i>P</i> value
MiP preventive strategy	Standard IPTp-SP	1		1	
	CSST/IPTp-SP	0.94 (0.82-1.10)	.479	0.95 (0.82-1.10)	.459
Gravidity	Multigravid	1			
	Secundigravid	1.11 (0.91-1.35)	.291		
	Primigravid	0.97 (0.78-1.19)	.756		
Mother's age	>30	1			
	21-30	1.01 (0.84-1.20)	.932		
	≤20	0.97 (0.78-1.20)	.763		
ITN use	No	1			
	Yes	0.99 (0.83-1.18)	.892		
Birth season	Low-transmission	1		1	
	High-transmission	0.88 (0.75-1.02)	.091	0.91 (0.79-1.06)	.229
Newborn sex	Male	1			
	Female	0.98 (0.85- 1.14)	.811		

NOTE. MiP, malaria in pregnancy; ITN, insecticide treated net; IRR, incidence rate ratio; CI, confidence interval

* Adjusted by variables that showed a *P* value < .1 in univariate analysis.

486

487

488

489

490

491

492 **Table 5: Stratified analyses of the effect of CSST/IPTp-SP on the incidence of NMFs**

493

CSST/IPTp-SP vs IPTp-SP (ref)		Unadjusted	<i>P</i> value	Adjusted*	<i>P</i> value
		stratum-specific		stratum-specific	
		IRR (95% CI)		IRR (95% CI)	
By birth season	Low-transmission	1.00 (0.76-1.32)	.977	1.02 (0.77-1.34)	.887
	High-transmission	0.80 (0.64-0.99)	.039	0.79 (0.64-0.98)	.031
By gravidity	Multigravid	0.81 (0.65-0.99)	.042	0.78 (0.63-0.97)	.027
	Secundigravid	0.82 (0.55-1.20)	.281	0.83 (0.56-1.23)	.357
	Primigravid	1.35 (0.92-1.99)	.130	1.35 (0.92-1.99)	.119

NOTE. IRR, incidence rate ratio; ref, reference

*Adjusted by gravidity or by birth season

494

495

496

497

498

499

500

501

502

503

504

505

506 **Figures**

507

508 **Figure 1: Study flow diagram.** Infants born from pregnant women participating in a randomized-
509 cluster trial (CSST/IPTp-SP vs standard IPTp) [14] were recruited into the study at birth and
510 followed-up until 12 months of age. Lost to follow-up are infants who did not complete the 12-
511 months follow-up. They were considered as censored observations at the time of the last visit in
512 survival analysis. Neonatal deaths and twins were excluded from the analysis. *Not included in the
513 survival analysis. ** Included in the survival analysis.

514

515 **Figure 2: Kaplan-Meier survival curves for time-to-first clinical malaria episode during the**
516 **first year of life according to MiP prevention strategy by birth season.** Infants born during
517 malaria low transmission season (A) and born during malaria high transmission season (B) were
518 followed-up for 12 months.

519